Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health in China. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products in development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.
Metrics to compare | 688221 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688221PeersSector | |
---|---|---|---|---|
P/E Ratio | −42.5x | −19.8x | −0.5x | |
PEG Ratio | −1.10 | 0.75 | 0.00 | |
Price/Book | 7.4x | 6.8x | 2.6x | |
Price / LTM Sales | 60.6x | 20.9x | 3.3x | |
Upside (Analyst Target) | - | 0.3% | 45.4% | |
Fair Value Upside | Unlock | −15.6% | 7.7% | Unlock |